However, voice realisations have fallen steeply due to competitive pressures leading to a fall in ARPM
Business model is robust and will lead to financials growing at a healthy pace in the next few years
Recent correction an opportunity to add a quality stock to your portfolio, even amid uncertainty
The company is on course to improving profitability but any move to expand smaller recharge options to subsidise set-top box charges by competition would be a major negative
Street to await improvement in room rents and occupancy, even as it gives nod to deleverage plans
March quarter results likely to be muted, further correction good opportunity to invest
Higher exports and content per vehicle coupled with adoption of new technologies should drive up realisations and revenue growth
Expectations of strong freight traffic growth and GST implementation, plus its extensive network and tight cost control, should enable robust revenue and profit growth
Monetisation of inhaler portfolio, domestic growth would be key
Launches from R&D portfolio could be a medium-term trigger; recent buy will boost domestic growth
Better quality and quantity of spectrum vis-a-vis competition must reflect on revenues, margins
Apart from operational gains, having retail arms under a listed firm would boost ABN's valuation
New products may improve share in economy and sports segments
FY15 revenues below estimates; order book expected to double in two years
The company is looking at smaller ticket sizes and expects its core market of Bengaluru to stay resilient going ahead
Though benchmark indices saw fresh highs, many leading stocks hit new lows
Company expected to outperform sector in FY16, on the back of new launches in key segments
Proposed listing of subsidiary Syngene and commissioning of Malaysian unit are positives
Historical trend shows these companies have given handsome returns to investors after listing, in most cases
Analysts sceptical of company's high valuations, volume and revenue growth prospects